{"filing":{"accession_number":"0001193125-26-357087","cik":"0001498382","ticker":"HURA","company_name":"TuHURA Biosciences, Inc./NV","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-18","primary_document":"hura-20260818.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526357087/hura-20260818.htm"},"events":[{"id":28589,"run_id":26160,"accession_number":"0001193125-26-357087","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"TuHURA Biosciences issued 1,878,287 unregistered shares of common stock to Parkview Holdings as a fee for a $50 million revolving credit facility, relying on Section 4(a)(2) and Regulation D exemptions.","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30585,"accession_number":"0001193125-26-357087","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TuHURA is disclosing the issuance of 1,878,287 unregistered shares of common stock to Parkview Holdings as a fee for a $50 million revolving credit facility, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement tied to debt financing, material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:04:41.465236+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":28590,"run_id":26160,"accession_number":"0001193125-26-357087","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"TuHURA Biosciences held its 2026 Annual Meeting of Stockholders on August 18, 2026, with all six proposals passing by requisite majorities: election of six directors (James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler), approval of Nasdaq-required share issuance, advisory vote on executive compensation, say-on-frequency vote, auditor ratification, and adjournment.","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30586,"accession_number":"0001193125-26-357087","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of TuHURA Biosciences' 2026 Annual Meeting of Stockholders held on August 18, 2026, including voting outcomes on six proposals: election of six directors (James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler), approval of Nasdaq-required share issuance, advisory vote on executive compensation, say-on-frequency vote, auditor ratification, and an adjournment proposal. The filing provides detailed vote tallies for each proposal, confirming that all proposals passed with requisite majorities. This is a classic shareholder vote results disclosure material to investors' understanding of governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:04:41.465236+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30585,"accession_number":"0001193125-26-357087","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TuHURA is disclosing the issuance of 1,878,287 unregistered shares of common stock to Parkview Holdings as a fee for a $50 million revolving credit facility, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement tied to debt financing, material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:04:41.465236+00:00","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-08-19"},{"id":30586,"accession_number":"0001193125-26-357087","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of TuHURA Biosciences' 2026 Annual Meeting of Stockholders held on August 18, 2026, including voting outcomes on six proposals: election of six directors (James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler), approval of Nasdaq-required share issuance, advisory vote on executive compensation, say-on-frequency vote, auditor ratification, and an adjournment proposal. The filing provides detailed vote tallies for each proposal, confirming that all proposals passed with requisite majorities. This is a classic shareholder vote results disclosure material to investors' understanding of governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:04:41.465236+00:00","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-08-19"}]}